B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.

Martine Piccart-Gebhart,Philippe Aftimos,François Duhoux,Hans Wildiers,Nicolas Isambert,Mario Campone,Diego Tosi,Andrea Varga,Valentina Boni,Bernard Doger,Javier Garcia Corbacho,Begoña Jiménez-Rodríguez,Manuel Ruiz Borrego,Cristina Saura,Hendrik-Tobias Arkenau,Andrew M Wardley,Iñaki F. Trocóniz,Monica Binaschi,Cecilia Simonelli,Andrea Pellacani

B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.

2019

TPS1101Background: MEN1611 is a potent, selective class I inhibitor of PI3K, a key enzyme in the transduction of various extracellular growth factor signals essential for cell survival and apoptosi...

Keywords:

Trastuzumab
PI3K/AKT/mTOR pathway
Oncology
Fulvestrant
Pathology
Internal medicine
Metastatic breast cancer
Medicine
Transduction (genetics)
Enzyme
Cancer research
Growth factor
Extracellular

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations